European Respiratory Journal

Article	Citations
The right ventricle tamed	1024
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	751
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	633
Similarity network fusion for the integration of multi-omics and microbiomes in respiratory disease	371
Chymase-1: a “MAST”-er switch in COPD?	332
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	233
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence	205
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	195
Missing airways, ventilation defects and conductive airway physiology in asthma	166
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	157
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	144
A breath of the future: a novel human model for COPD and beyond	141
The lung that rules the heart	140
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	127
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	123
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	123
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?	117
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	115
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	114
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	111
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	110
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	106
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	102
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	93
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	92

Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	91
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	90
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	89
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	84
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	83
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	81
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	81
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	80
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	80
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	80
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	80
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	79
The environmental impact of inhaled therapy: making informed treatment choices	78
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	77
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	76
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	76
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	75
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	75
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	74
Treatment algorithm for pulmonary arterial hypertension	74
The association between immunosuppressants and outcomes of COVID-19	73
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	72
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis	72
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	72
Prognostic phenotypes of early-stage lung adenocarcinoma	72
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	72
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	71
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	71
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	71
The limits of normal of pulmonary arterial wedge pressure	71
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	70
Screening asymptomaticBMPR2mutation carriers: a new frontier for pulmonary hypertension physicians?	69
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines	69
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	65
Pleural mesothelioma: surgery questioned again?	64
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	61
List ofEuropean Respiratory Journalpeer reviewers 2023	59
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?	58
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.	57
The coming-of-age of bedaquiline: a tale with an open ending	56
Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures	56
FEV1Q: what (even) is normal lung function?	56
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis	55
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	55
CPAP recall and cancer risk: should we be concerned?	55
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	55
Particulate matter–related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling	55
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	54
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	54
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis	53

Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	53
Childhood asthma: pathogenesis and phenotypes	53
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	53
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	52
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19	52
Metabolomics in pulmonary medicine: extracting the most from your data	51
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	51
Is tezepelumab more than just an anti-eosinophil drug?	51
Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension	51
Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis	48
The dawn of the omics era in human precision-cut lung slices	48
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia	48
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	48
Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!	47
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	47
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	47
Oral corticosteroids in asthma and beyond: moving forward	46
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	46
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	46
“Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts.” Qingzhu Sun, Lei Fang, Mic	45
Unravelling the unmet needs of patients with severe dyspnoea: a case for palliative oxygen	44
Oxygen therapy target ranges: finding the balance	44
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	43
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	43
Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis	43
Reply to: Cause or consequence?	43
Cardiopulmonary response to exercise in adults born very preterm	43
Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study	42
Bronchoconstriction with inhaled ATP in healthy volunteers	42
ERJPodcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	42
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	42
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	42
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?	42
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	41
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease	41
Multitasking within the airway epithelium	41
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index	41
COVID-19 changed the world – without changing CTEPH	41
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	40
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	40
Tailored approaches facilitate high completion of tuberculosis infection treatment among migrants	40
ERJPodcast January 2024: The microbiome in early life and childhood asthma	40
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	40
European Respiratory Society guidelines for the diagnosis of asthma in adults	39
Transcriptomic clustering of critically ill COVID-19 patients	39
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity	38
Epigenetic Age among U.S. Adults with Chronic Respiratory Diseases: Results from NHANES 1999-2002	38
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	38
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	38
Flavonoid intakes inversely associate with COPD in smokers	38
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	37
Saliva molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy	37
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children	37
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	37
Moving the dial on identifying endotypes of asthma from early life	37
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	37
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	37
Air pollution and COPD: GOLD 2023 committee report	37
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	37
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	37
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content	37
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1	36
Aspergillussensitisation: an underappreciated treatable trait in airway disease	36
Evolving diagnostic techniques in mediastinal lymphadenopathy: is mediastinal cryobiopsy the new kid on the block?	36
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	36
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	35
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	35
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	35
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients	35
Technical standards for respiratory oscillometry and bronchodilator response cut-offs	34
Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: an F-MISO PET/CT study	34
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	34
Primary spontaneous pneumothorax: does size matter?	34
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	33
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	33
Lung transplantation for acute respiratory distress syndrome: a retrospective European cohort study	33
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	33
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	33
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	33
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	33

Relieving dyspnoea through the brain	32
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	32
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	32
The role of precision medicine in interstitial lung disease	32
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	31
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	31
Asthma, COPD and their overlap: coexistence or something more?	31
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	31
Incidence of interstitial lung abnormalities: the MESA Lung Study	31
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium	31
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series	31
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	30
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	30
List ofEuropean Respiratory Journalpeer reviewers 2022	30
Ex vivodelivery of regulatory T-cells for control of alloimmune priming in the donor lung	30
Pulmonary hypertension associated with left heart disease	30
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	30
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases	30
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	30
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	29
ERJPodcast December 2023: Year in review	29
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	29
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	29
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	29
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	29
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	29
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	29
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside	29
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands	29
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury	29
ERJPodcast July 2023: The HISTORIC study	29
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	29
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?	28
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	28
Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries	28
Ensuring availability of respiratory medicines in times of European drug shortages	28
Association of blood trihalomethane concentrations with asthma in US adolescents: nationally representative cross-sectional study	28
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma	28
All roads lead to COPD… or not?	28
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study	28
Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis	28
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	27
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	27
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	27
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	27
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	27
A randomised trial of prednisoloneversusprednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma	27
Integrating hot topics and implementation of treatable traits in asthma	27
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	27
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	27
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	27
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	26
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir	26
R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life	26
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	26
ERS statement on paediatric long-term noninvasive respiratory support	26
Progressive pulmonary fibrosis: an expert group consensus statement	26
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	26
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	26
Sleep apnoea in the elderly: a great challenge for the future	26
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	26
Vulnerability to acid reflux of the airway epithelium in severe asthma	25
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	25
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	25
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	25
The interface in home non-invasive ventilation: is the nasal mask better?	25
Management of pulmonary hypertension in special conditions	25
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	25
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	24
Drug-induced lung disease: unwanted collateral damage	24
TB or not TB: does AI have an answer for children?	24
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	24
Heart or lungs? Why not both!	24
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	24
Latent COPD: a proposed new term in the disease nomenclature	24
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	24
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	24
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 2101814	24
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	23
Impact of a rare respiratory diseases reference centre set-up on primary ciliary dyskinesia care pathway	23
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	23
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	23
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter,et al.Eur Respir J2021; 58: 2004314	23
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	23
Endothelial cells in pulmonary fibrosis: more than a bystander	23
Increasing physical activity in severe asthma: a systematic review and meta-analysis	22
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?	22
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study	22
European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis	22
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	22
Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic	22
The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study	22
CPAP resumption after a first termination and impact on all-cause mortality in France	22
The paradox of the safer cigarette: understanding the pulmonary effects of electronic cigarettes	22